The cell biology of parathyroid hormone in osteoblasts

Current Osteoporosis Reports

Volumn 6, Issue 2, 2008, Pages 72-76

  Kousteni, Stavroula ^b   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; SCLEROSTIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN;

BIOSYNTHESIS; CANCELLOUS BONE; CATABOLISM; CELL COUNT; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL FATE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CORTICAL BONE; CYTOLOGY; GENE ACTIVATION; HORMONE ACTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; PERIOSTEUM; PROTEIN DEGRADATION; REVIEW; RODENT; SIGNAL TRANSDUCTION; SKELETON; STEM CELL; ANIMAL; BONE DEVELOPMENT; PHYSIOLOGY;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OSTEOBLASTS; OSTEOGENESIS; PARATHYROID HORMONE; WNT PROTEINS;

EID: 58149134327     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0013-9     Document Type: Review

References (38)

1. Potts JT: ParatPyroid hormone: past and present. J Endocrinol 2005, 187:311-325.
2. Gesty-Palmer D, Chen M, Reiter E, et al.: Distinct betaarrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006, 281:10856-10864.
3. Gensure RC, Gardella TJ, Juppner H: Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005, 328:666-678.
4. Qin L, Li X, Ko JK, Partridge NC: Parathyroid hormone uses multiple mechanisms to arrest cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 2005, 280:3104-3111.
5. Knopp E, Troiano N, Bouxsein M, et al.: The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 2005, 146:1983-1990.
6. Datta NS, Chen C, Berry JE, McCauley LK: PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 2005, 20: 1051-1064.
7. Wang YH, Liu Y, Rowe DW: Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am J Physiol Endocrinol Metab 2007, 292:E594-E603.
8. Datta NS, Pettway GJ, Chen C, et al.: Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 2007, 22:951-964.
9. Ogita M, Dworakowski E, Bilezikian JP, Kousteni S: Proliferation and differentiation of periosteal osteoblast progenitors are differentially regulated by sex steroids and intermittent PTH administration. J Bone Miner Res 2007, 22:S95.
10. Nakazawa T, Nakajima A, Shiomi K, et al.: Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37:711-719.
11. Valenta A, Roschger P, Fratzl-Zelman N, et al.: Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 2005, 37:87-95.
12. Pettway GJ, Schneider A, Koh AJ, et al.: Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 2005, 36:959-970.
13. Kulkarni NH, Halladay DL, Miles RR, et al.: Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005, 95:1178-1190.
14. Guo J, Schipani E, Liu M, et al.: Suppression of Dkk1 is not essential for PTH-mediated activation of canonical Wnt signaling in bone. J Bone Miner Res 2005, 20:S2.
15. Barnes GL, Kakar S, Gerstenfeld LC, Einhorn TA: PTH mediates early stem cell recruitment during fracture repair. J Bone Miner Res 2005, 20:S102.
16. Shimizu E, Selvamurugan N, Westendorf JJ, Partridge NC: Parathyroid hormone regulates histone deacetylases in osteoblasts. Ann N Y Acad Sci 2007, 1116:349-353.
17. Li X, Liu H, Qin L, et al.: Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007, 282:33086-33097.
18. Chan GK, Deckelbaum RA, Bolivar I, et al.: PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology 2001, 142:4900-4909.
19. Rickard DJ, Wang FL, Rodriguez-Rojas AM, et al.: Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39:1361-1372.
20. Bellido T, Ali AA, Plotkin LI, et al.: Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278:50259-50272.
21. Calvi LM, Sims NA, Hunzelman JL, et al.: Activated parathyroid hormone/ parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001, 107:277-286.
22. Stanislaus D, Devanarayan V, Hock JM: In vivo comparison of activated protein-1 gene activation in response to human parathyroid hormone (hPTH)(1-34) and hPTH(1-84) in the distal femur metaphyses of young mice. Bone 2000, 27:819-826.
23. Lindsay R, Zhou H, Cosman F, et al.: Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22:495-502.
24. Tobimatsu T, Kaji H, Sowa H, et al.: Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 2006, 147:2583-2590.
25. Kakar S, Einhorn TA, Vora S, et al.: Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903-1912.
26. Bodine PV, Seestaller-Wehr L, Kharode YP, et al.: Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 2007, 210:352-357.
27. Sawakami K, Robling AG, Ai M, et al.: The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006, 281:23698-23711.
28. Iwaniec UT, Wronski TJ, Liu J, et al.: PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 2007, 22:394-402.
29. Kato M, Patel MS, Levasseur R, et al.: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314.
30. Bellido T, Ali AA, Gubrij I, et al.: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
31. Keller H, Kneissel M: SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
32. Loots GG, Kneissel M, Keller H, et al.: Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15:928-935.
33. Leupin O, Kramer I, Collette NM, et al.: Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007, 22:1957-1967.
34. O'Brien CA, Plotkin LI, Vyas K, et al.: Activation of PTH receptor I in osteocytes suppresses Sost expression and increases bone mass in transgenic mice. J Bone Miner Res 2006, 21:S4.
35. Yamaguchi M, Ogata N, Shinoda Y, et al.: Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 2005, 146:2620-2628.
36. Yakar S, Bouxsein ML, Canalis E, et al.: The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006, 189:289-299.
37. Wang Y, Nishida S, Boudignon BM, et al.: IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007, 22:1329-1337.
38. Jilka RL: Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40:1434-1446.